AU2001249835A1 - Diagnosis and treatment of alzheimer's disease - Google Patents
Diagnosis and treatment of alzheimer's diseaseInfo
- Publication number
- AU2001249835A1 AU2001249835A1 AU2001249835A AU4983501A AU2001249835A1 AU 2001249835 A1 AU2001249835 A1 AU 2001249835A1 AU 2001249835 A AU2001249835 A AU 2001249835A AU 4983501 A AU4983501 A AU 4983501A AU 2001249835 A1 AU2001249835 A1 AU 2001249835A1
- Authority
- AU
- Australia
- Prior art keywords
- alzheimer
- diagnosis
- disease
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19450400P | 2000-04-03 | 2000-04-03 | |
US60/194,504 | 2000-04-03 | ||
US25364700P | 2000-11-28 | 2000-11-28 | |
US60/253,647 | 2000-11-28 | ||
PCT/US2001/010908 WO2001075454A2 (en) | 2000-04-03 | 2001-04-03 | Diagnosis and treatment of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001249835A1 true AU2001249835A1 (en) | 2001-10-15 |
Family
ID=26890092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001249835A Abandoned AU2001249835A1 (en) | 2000-04-03 | 2001-04-03 | Diagnosis and treatment of alzheimer's disease |
Country Status (5)
Country | Link |
---|---|
US (2) | US20020164668A1 (en) |
EP (1) | EP1325338A2 (en) |
JP (1) | JP2004505609A (en) |
AU (1) | AU2001249835A1 (en) |
WO (1) | WO2001075454A2 (en) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7015004B2 (en) * | 2001-11-23 | 2006-03-21 | Syn X Pharma, Inc. | Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance |
US6890763B2 (en) | 2001-04-30 | 2005-05-10 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons |
US20020160423A1 (en) * | 2001-04-30 | 2002-10-31 | George Jackowski | Biopolymer marker indicative of disease state having a molecular weight of 1536 daltons |
US6627606B2 (en) * | 2001-04-30 | 2003-09-30 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons |
US20020160420A1 (en) * | 2001-04-30 | 2002-10-31 | George Jackowski | Process for diagnosis of physiological conditions by characterization of proteomic materials |
US20040198950A1 (en) * | 2001-04-30 | 2004-10-07 | George Jackowski | Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons |
US6599877B2 (en) * | 2001-04-30 | 2003-07-29 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1020 daltons |
US6627608B2 (en) | 2001-04-30 | 2003-09-30 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons |
US7008800B2 (en) * | 2001-04-30 | 2006-03-07 | Artemis Proteomics, Ltd. | Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons |
SG121733A1 (en) * | 2001-10-03 | 2006-05-26 | Pfizer Prod Inc | Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease |
WO2003032894A2 (en) * | 2001-10-12 | 2003-04-24 | Pfizer Products Inc. | Method of monitoring neuroprotective treatment |
US7132244B2 (en) | 2001-11-21 | 2006-11-07 | Syn X Pharma, Inc. | Betaine/GABA transport protein biopolymer marker indicative of insulin resistance |
US7314762B2 (en) | 2001-11-21 | 2008-01-01 | Nanogen, Inc. | Apolipoprotein biopolymer markers indicative of insulin resistance |
US7074576B2 (en) * | 2001-11-23 | 2006-07-11 | Syn X Pharma, Inc. | Protein biopolymer markers indicative of alzheimer's disease |
US7052849B2 (en) * | 2001-11-23 | 2006-05-30 | Syn X Pharma, Inc. | Protein biopolymer markers predictive of insulin resistance |
US20030100009A1 (en) * | 2001-11-23 | 2003-05-29 | George Jackowski | Inter alpha trypsin inhibitor biopolymer markers indicative of insulin resistance |
US7125678B2 (en) * | 2001-11-23 | 2006-10-24 | Nanogen, Inc. | Protein biopolymer markers predictive of type II diabetes |
US7179605B2 (en) | 2001-11-23 | 2007-02-20 | Nanogen Inc. | Fibronectin precursor biopolymer markers indicative of alzheimer's disease |
WO2003046566A2 (en) * | 2001-11-23 | 2003-06-05 | Syn.X Pharma, Inc. | Pedf biopolymer markers predictive of alzheimers disease |
US7026129B2 (en) * | 2001-11-23 | 2006-04-11 | Syn X Pharma, Inc. | IG lambda biopolymer markers predictive of Alzheimers disease |
US20030113808A1 (en) * | 2001-12-13 | 2003-06-19 | George Jackowski | Apolipoprotein biopolymer markers predictive of alzheimers disease |
DK1388734T3 (en) | 2002-08-01 | 2004-05-03 | Mtm Lab Ag | Method for solution-based diagnosis |
DE60322719D1 (en) * | 2002-08-23 | 2008-09-18 | Bayer Healthcare Ag | POLYPEPTIDE BIOMARKERS FOR THE DIAGNOSIS OF MORBUS ALZHEIMER |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
EP1604210A2 (en) * | 2003-03-18 | 2005-12-14 | BioVisioN AG | Method for detecting alzheimer's disease and corresponding peptides and detection reagents |
US8597911B2 (en) * | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
CN101014358A (en) * | 2003-10-29 | 2007-08-08 | 约翰·霍普金斯大学 | Biological activity of pigment epithelium-derived factor and methods of use |
WO2005086947A2 (en) | 2004-03-10 | 2005-09-22 | Trinity Therapeutics, Inc. | Method for inhibiting immune complex formation in a subjetc |
WO2005095441A1 (en) | 2004-03-31 | 2005-10-13 | National Institute Of Advanced Industrial Science And Technology | Epithelial cell growth promoter |
WO2006005591A1 (en) * | 2004-07-12 | 2006-01-19 | Geneprot Inc. | Polypeptide species useful for the treatment of neurological disorders |
WO2006029838A2 (en) * | 2004-09-14 | 2006-03-23 | Geneprot Inc. | Secreted polypeptide species involved in alzheimer’s disease |
WO2006074787A2 (en) * | 2004-12-27 | 2006-07-20 | Geneprot Inc. | Polypeptide species useful for the treatment of neurological disorders |
WO2006069739A2 (en) * | 2004-12-27 | 2006-07-06 | Geneprot Inc. | Polypeptide species useful for the treatment of neurological disorders |
WO2006106905A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
US20080307537A1 (en) * | 2005-03-31 | 2008-12-11 | Dana-Farber Cancer Institute, Inc. | Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions |
AU2006261911B2 (en) * | 2005-06-24 | 2010-05-13 | Cadila Healthcare Limited | Thrombospondin-1 derived peptides and treatment methods |
EP1940436B1 (en) * | 2005-09-06 | 2013-12-04 | Trinity Therapeutics, Inc. | Methods for treating immune mediated neurological diseases |
KR20180058863A (en) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | Monoclonal antibodies against amyloid beta protein and uses thereof |
RU2442793C2 (en) * | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES |
US20070166765A1 (en) * | 2006-01-16 | 2007-07-19 | Christian Rohlff | Protein isoforms and uses thereof |
DK2009101T3 (en) * | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
US11046784B2 (en) * | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008104386A2 (en) * | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
SI2202245T1 (en) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
MY163473A (en) * | 2007-09-26 | 2017-09-15 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
WO2010107110A1 (en) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | Antibody constant region variant |
JP5787446B2 (en) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | Antibody constant region variants |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
ES2684475T3 (en) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteins that bind to beta amyloid |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
CN105859889B (en) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | Multispecific antigen-binding molecules having a function replacing the function of factor VIII |
TWI638833B (en) | 2010-11-30 | 2018-10-21 | 中外製藥股份有限公司 | Cell damage induction treatment |
US9839671B2 (en) | 2012-01-13 | 2017-12-12 | The University Of Birmingham | Peptide and uses therefor |
GB2515334A (en) * | 2013-06-20 | 2014-12-24 | Neuro Bio Ltd | Biomarkers for alzheimer's Disease |
BR112016006197B1 (en) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY |
CN105334300A (en) * | 2014-08-01 | 2016-02-17 | 沈德铭 | Rapid method for screening treatment effectiveness of biological source substance |
WO2016159213A1 (en) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | Method for producing polypeptide hetero-oligomer |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of fc region-containing polypeptide |
US11543418B2 (en) | 2017-07-13 | 2023-01-03 | Kazuhiko Uchida | Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using biomarker |
CN113111874A (en) * | 2021-04-01 | 2021-07-13 | 上海市第一人民医院 | Rapid classification method for lateral images of lumbar vertebrae |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811310A (en) * | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
US5272055A (en) * | 1991-12-24 | 1993-12-21 | The University Of Kentucky Research Foundation | Detection of Alzheimer's disease and other diseases using a photoaffinity labeling method |
US5429947A (en) * | 1992-06-17 | 1995-07-04 | Merril; Carl R. | Diagnosing Alzheimer's disease and schizophrenia |
TR199701203T1 (en) * | 1995-04-19 | 1998-03-21 | Acorda Therapeutics | CNS n�rit b�y�me mod�lat�rleri ve bile�imleri. |
JPH11507845A (en) * | 1997-02-13 | 1999-07-13 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Neural cell adhesion molecule splicing variant |
AU6465798A (en) * | 1997-03-14 | 1998-09-29 | Neuromark | Diagnosing neurologic disorders |
AU3762699A (en) * | 1998-04-27 | 1999-11-16 | Pacific Northwest Cancer Foundation | (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
-
2001
- 2001-04-03 WO PCT/US2001/010908 patent/WO2001075454A2/en not_active Application Discontinuation
- 2001-04-03 EP EP01923111A patent/EP1325338A2/en not_active Withdrawn
- 2001-04-03 US US09/826,290 patent/US20020164668A1/en not_active Abandoned
- 2001-04-03 JP JP2001572879A patent/JP2004505609A/en not_active Withdrawn
- 2001-04-03 AU AU2001249835A patent/AU2001249835A1/en not_active Abandoned
-
2005
- 2005-03-11 US US11/078,000 patent/US20070015217A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001075454A3 (en) | 2003-05-08 |
EP1325338A2 (en) | 2003-07-09 |
JP2004505609A (en) | 2004-02-26 |
US20070015217A1 (en) | 2007-01-18 |
WO2001075454A2 (en) | 2001-10-11 |
US20020164668A1 (en) | 2002-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001249835A1 (en) | Diagnosis and treatment of alzheimer's disease | |
HUP1500560A2 (en) | Thioflavin derivatives and their use in diagnosis and treatment of alzheimer's disease | |
EP1392287B8 (en) | Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease | |
HUP0103654A2 (en) | Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease | |
AU2003220096A1 (en) | Methods for alzheimer's disease treatment and cognitive enhancement | |
HUP0003852A3 (en) | Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias | |
AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
AU3173301A (en) | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity | |
AU2002239765A1 (en) | Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease | |
AU2001236592A1 (en) | Methods for diagnosis of alzheimer's disease | |
AU2002222108A1 (en) | Diagnosis and treatment of alzheimer's disease | |
AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
AU2002326813A1 (en) | Diagnosis and treatment of vascular disease | |
AU5550800A (en) | Diagnosis and treatment of alzheimer's disease | |
AU2001257406A1 (en) | Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941 | |
AU2002302238A1 (en) | A method of treatment of alzheimer's disease and device therefor | |
AU2003248660A1 (en) | Treatment of vascular dysfunction and alzheimer's disease | |
AU2002341604A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002312667A1 (en) | Individualization of therapy with alzheimer's disease agents | |
PL377110A1 (en) | Prevention and treatment of alzheimer's disease | |
GB9908059D0 (en) | Diagnosis and treatment of diseases | |
AU2001253024A1 (en) | Diagnosis and treatment of gastrointestinal disease | |
AU2002319591A1 (en) | Diagnosis and treatment of vascular disease | |
GB0008162D0 (en) | Diagnosis and treatment of alzheimer's disease | |
AU2002312797A1 (en) | Peptide for the diagnosis and therapy of alzheimer's disease |